Allergan (NYSE:AGN) was downgraded by Argus from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

Other equities research analysts also recently issued reports about the company. Wells Fargo & Company reaffirmed an “outperform” rating and set a $280.00 price objective (up from $270.00) on shares of Allergan in a report on Wednesday, August 9th. Morgan Stanley set a $200.00 target price on Allergan and gave the stock a “buy” rating in a report on Wednesday. Vetr downgraded Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 target price on the stock. in a report on Wednesday. UBS reissued an “outperform” rating and issued a $275.00 target price on shares of Allergan in a report on Wednesday, August 9th. Finally, BidaskClub downgraded Allergan from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $241.56.

Shares of Allergan (NYSE AGN) opened at $168.00 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The firm has a market capitalization of $54,636.75, a P/E ratio of 10.65, a price-to-earnings-growth ratio of 1.10 and a beta of 1.11. Allergan has a 1-year low of $160.07 and a 1-year high of $256.80.

Allergan (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.06 by $0.09. The company had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.32 earnings per share. equities research analysts predict that Allergan will post 16.28 EPS for the current fiscal year.

Allergan announced that its Board of Directors has approved a stock repurchase plan on Monday, September 25th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its stock is undervalued.

In other Allergan news, insider William Meury sold 11,807 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher J. Coughlin purchased 10,000 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The stock was purchased at an average cost of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. Insiders own 0.36% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Allergan by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after purchasing an additional 482,220 shares during the period. Northern Trust Corp boosted its stake in Allergan by 8.8% in the 2nd quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock worth $1,092,189,000 after purchasing an additional 364,722 shares during the period. Edgewood Management LLC boosted its stake in Allergan by 24.3% in the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock worth $911,192,000 after purchasing an additional 869,248 shares during the period. Baupost Group LLC MA boosted its stake in Allergan by 21.9% in the 3rd quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock worth $607,513,000 after purchasing an additional 531,600 shares during the period. Finally, Epoch Investment Partners Inc. boosted its stake in Allergan by 1.0% in the 3rd quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock worth $370,060,000 after purchasing an additional 17,068 shares during the period. 81.34% of the stock is owned by institutional investors.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/07/allergan-agn-rating-lowered-to-hold-at-argus.html.

About Allergan

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.